By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Non-cardioselective beta blockers > Nadolol > Nadolol Dosage
Non-cardioselective beta blockers
https://themeditary.com/dosage-information/nadolol-dosage-6132.html

Nadolol Dosage

Drug Detail:Nadolol (Nadolol [ na-doe-lol ])

Drug Class: Non-cardioselective beta blockers

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Angina Pectoris

Initial dose: 40 mg orally once a day; may be increased by 40 to 80 mg every 3 to 7 days until optimum response is obtained or pronounced heart rate reduction occurs
Maintenance dose: 40 to 80 mg orally once a day; up to 240 mg once a day may be required
Maximum dose: 240 mg/day

Usual Adult Dose for Hypertension

Initial dose: 40 mg orally once a day; may be increased in 40 to 80 mg increments until optimum blood pressure reduction is achieved
Maintenance dose: 40 to 80 mg orally once a day; up to 320 mg once a day may be required

Renal Dose Adjustments

CrCl greater than 50 mL/min/1.73 m2: Administer every 24 hours
CrCl 31 to 50 mL/min/1.73 m2: Administer every 24 to 36 hours
CrCl 10 to 30 mL/min/1.73 m2: Administer every 24 to 48 hours
CrCl less than 10 mL/min/1.73 m2: Administer every 40 to 60 hours

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNING:

  • DISCONTINUING THERAPY: Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy. When discontinuing chronically administered nadolol, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1 to 2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, nadolol administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly even in patients treated only for hypertension.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Storage requirements: Protect from light.

Patient advice: Caution patients against interruption or cessation of therapy without a physician's advice.

Share this Article
Latest News
Medical News

Could lactose intolerance be giving you nightmares?

Jul 01, 2025
Measles risk while traveling: How to avoid infection
Heart disease: Omega-3 and omega-6 fatty acids linked to inflammatory
Alzheimer's: Insulin resistance test may predict cognitive decline
New oral drug may treat diabetes, obesity without muscle loss
Could drinking instant coffee affect your vision as you age?
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by